**4. Conclusion(s)**

*A. baumannii* is one of the ESKCAPE pathogens responsible for nosocomial and community-acquired infections, with the incidence of MDR and virulent clones increasingly worldwide. The enormous adaptability of *A. baumannii*, as well as the remarkable ability to acquire determinants of resistance, allied to your innate ability to form biofilms, contributes to the inefficiency of most current therapeutic strategies, determining the transition to the "post-antibiotic era" and highlighting the necessity to develop new therapeutic approaches*.* In this context, natural and synthetic AMPs emerge as potential next-generation antibiotics to mitigate a wide array of microbial infections, including those caused by MDR *A. baumannii* strains. Moreover, the antimicrobial activity of these peptides can be effectively increased by minor modifications through the development of computer science and bioinformatics. The synthetic AMPs present a promising solution to overcome the drawbacks of using natural AMPs. They contain critical features based on natural AMPs, with slight modifications to achieve higher antimicrobial efficiency and improved chemical stability. In this research, we observed the main properties of anti-*A. baumannii* peptides with some common characteristics, such as 1. The α-helical structure was predominant. 2. Most peptides have a positive charge, and in many cases, there is a direct relationship between an increased positive charge and your activity. 3. The action mechanisms of these peptides are direct membrane attack and intracellular targeting or both simultaneously. Unfortunately, considerable experimental data describe how bacteria can develop resistance to AMPs, such as colistin and polymyxin B in *A. baumannii*. Since AMPS are considered potential novel antimicrobial drugs, understanding the mechanism of bacterial resistance to direct killing of AMPS is of great significance.
